These findings highlight Hsp90 as a central regulator of cardiac fibrosis, hypertrophy, inflammation, and metabolic dysfunction, suggesting that targeted modulation of Hsp90 could be a promising therapeutic strategy for cardiovascular and metabolic diseases. Here, HSP90AB1 is linked to metabolic disease.